People | February 22, 2022
PrecisionLife appoints Colin Stubberfield as SVP Drug Discovery
He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,
He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,
UCB plans to submit regulatory applications in Q3 2022
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Acute therapies continue to report strong growth compared to chronic ones.
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
Subscribe To Our Newsletter & Stay Updated
